Arteriocyte

Hopkinton, United States Founded: 2007 • Age: 19 yrs
Devices to facilitate blood component and bone marrow transplant
Request Access

About Arteriocyte

Arteriocyte is a company based in Hopkinton (United States) founded in 2007 by Donald Brown.. Arteriocyte has raised $15.11 million across 6 funding rounds from investors including HHS, Cleveland Clinic Innovations and DW Management Services. Arteriocyte offers products and services including Magellan, Influx, and InQu. Arteriocyte operates in a competitive market with competitors including Hemotune, Medcura, ExThera Medical, Lindis Blood Care and CytoPherx, among others.

  • Headquarter Hopkinton, United States
  • Founders Donald Brown
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $15.11 M (USD)

    in 6 rounds

  • Latest Funding Round
    $2.48 M (USD), Grant

    Mar 14, 2011

  • Investors
    HHS

    & 3 more

  • Employee Count
    Employee Count
  • Acquired by
    N/A

    (Oct 19, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Arteriocyte

Arteriocyte offers a comprehensive portfolio of products and services, including Magellan, Influx, and InQu. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

System for creating platelet-rich plasma and bone marrow therapies.

Allograft products for bone grafting and healing applications.

Biosynthetic bone graft for faster fusion in medical procedures.

Funding Insights of Arteriocyte

Arteriocyte has successfully raised a total of $15.11M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $2.48 million completed in March 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round Grant — $2.5M
  • First Round

    (01 Nov 2007)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2011 Amount Grant - Arteriocyte Valuation

investors

HHS
Mar, 2011 Amount Debt – Convertible - Arteriocyte Valuation

investors

Jul, 2009 Amount Series A - Arteriocyte Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Arteriocyte

Arteriocyte has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Cleveland Clinic Innovations and DW Management Services. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Health tech startups are supported through incubation services.
Founded Year Domain Location
-
Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Arteriocyte

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Arteriocyte

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Arteriocyte Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Arteriocyte

Arteriocyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemotune, Medcura, ExThera Medical, Lindis Blood Care and CytoPherx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of a device for blood purification
domain founded_year HQ Location
Developer of the device for controlling bleeding
domain founded_year HQ Location
Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking
domain founded_year HQ Location
Innovative solutions for safer blood transfusions are developed.
domain founded_year HQ Location
Cytopheresis systems for inflammatory conditions
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Arteriocyte

When was Arteriocyte founded?

Arteriocyte was founded in 2007.

Where is Arteriocyte located?

Arteriocyte is headquartered in Hopkinton, United States. It is registered at Hopkinton, Massachusetts, United States.

Is Arteriocyte a funded company?

Arteriocyte is a funded company, having raised a total of $15.11M across 6 funding rounds to date. The company's 1st funding round was a Series A of $100K, raised on Nov 01, 2007.

What does Arteriocyte do?

Arteriocyte Medical Systems, is a medical device company that develops products to accelerate healing in patients. Its lead product, Magellan Autologous Platelet Separator provides surgeons the ability to fractionate peripheral blood, or a mixture of blood and aspirated bone marrow from a patient. It also produces Demineralized Bone Matrix in the form of powder - MAR0Match or in the form of gel - MAR0Fuse. Other products include Magellan PRP to prepare Platelet Rich Plasma, and MAR0Max kit that provides the surgeon tools needed to Aspirate, Concentrate and Deliver a mixture of whole blood and bone marrow.

Who are the top competitors of Arteriocyte?

Arteriocyte's top competitors include Medcura, ExThera Medical and Lindis Blood Care.

What products or services does Arteriocyte offer?

Arteriocyte offers Magellan, Influx, and InQu.

Who are Arteriocyte's investors?

Arteriocyte has 3 investors. Key investors include HHS, Cleveland Clinic Innovations, and DW Management Services.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available